Search results
22 maj 2020 · We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
- Original Article Colchicine in Patients With Chronic Coronary Disease S.M. Nidorf and Others
Remdesivir for 5 or 10 Days in Patients with Severe...
- Free Full Text
Coronavirus disease 2019 (Covid-19) ... Beigel JH, Tomashek...
- Images in Clinical Medicine Auricular Hematoma A.L. Miller and M.S. Cohen
A 17-year-old boy presented with swelling and bruising of...
- Original Article Lineage-Independent Tumors in Bilateral Neuroblastoma T.H.H. Coorens and Others
Original Article Lineage-Independent Tumors in Bilateral...
- Interactive Medical Case a Patient With Fever and Dyspnea W.R. Matias and Others
This interactive case features a 60-year-old woman who...
- Perspective Shaping The Future of Veterans' Health Care L. McCauley and K.S. Ramos
Members of the U.S. military are at risk for a range of...
- Clinical Problem-Solving In The Absence of Proof S. Kushwaha and Others
Clinical Problem-Solving In The Absence of Proof S. Kushwaha...
- Images in Clinical Medicine Necrotizing Scleritis N. Lorenzana Blanco and N. Alejandre Alba
A 73-year-old woman with rheumatoid arthritis presented with...
- Original Article Colchicine in Patients With Chronic Coronary Disease S.M. Nidorf and Others
Najważniejsze informacje. • U dorosłych hospitalizowanych z powodu COVID-19, stosowanie remdesiwiru, w porównaniu z placebo (leczeniem pozorowanym) lub standardową opieką, ma prawdopodobnie niewielki lub żaden wpływ na ryzyko zgonu w ciągu 150 dni od rozpoczęcia leczenia.
22 gru 2021 · Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized...
5 lis 2020 · Methods: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days ...
20 paź 2020 · The antiviral remdesivir shortened recovery time for patients hospitalized with COVID-19, based on results from the completed trial. Researchers are now testing remdesivir in combination with antibodies and other medications.
30 lip 2020 · Recommendation 1 We suggest remdesivir rather than no remdesivir in patients with severe covid-19 Usual supportive care Remdesivir or 100 mg intravenously daily for 5-10 days No remdesivir Strong Weak Weak Strong Resource limited settings. Evidence profile. Individual considerations.
25 sty 2023 · Objectives: To assess the effects of remdesivir and standard care compared to standard care plus/minus placebo on clinical outcomes in patients treated for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
